Form 4: Teva Pharmaceutical Industries: EVP, CFO Eliyahu Sharon Kalif Reports Acquisition of Restricted Share Units

Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the acquisition of 183,169 restricted share units on January 28, 2025, convertible to ordinary shares, following the satisfaction of performance criteria.

Summary

• On January 28, 2025, Eliyahu Sharon Kalif, the EVP and Chief Financial Officer of Teva Pharmaceutical Industries, acquired 183,169 restricted share units.
• These restricted share units were received upon meeting the performance criteria of performance share units.
• Each restricted share unit represents the right to receive one ordinary share or its cash value, as determined by the Human Resources and Compensation Committee.
• The acquired restricted share units are subject to time-based vesting and will vest on March 4, 2025.
• The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one ordinary share.

Sentiment

Score: 6

Explanation: The document itself is neutral, as it's a regulatory filing. The acquisition of shares by an executive is generally a positive sign, suggesting confidence in the company, but it's a routine event.

Positives

• The acquisition of restricted share units by a key executive suggests confidence in the company's performance and future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of restricted share units on March 4, 2025, indicates a future event tied to the executive's continued employment and potentially the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates compensation practices at Teva and aligns executive incentives with shareholder value.

Comparison to Industry Standards

• Granting restricted share units to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders.
• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and performance criteria associated with these grants can vary widely based on company-specific goals and industry benchmarks.

Stakeholder Impact

• The acquisition of restricted share units by a key executive can positively influence shareholder sentiment, as it aligns management's interests with the company's performance.

Key Dates